Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-10-17 English
20FR12B
Regulatory Filings
2024-10-17 English
Telix Files Form 20-F Registration Statement for Nasdaq ADS 2 pages 183.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement by Telix Pharmaceuticals Limited regarding the filing of a Form 20-F registration statement with the U.S. SEC for a proposed Nasdaq ADS listing. It is a public announcement about a regulatory filing and listing plan, not the filing itself or a detailed financial report. The document is about the company's capital market activity (listing on Nasdaq) but explicitly states no capital raising or new shares issuance is involved. The document is approximately 8,160 characters, which is relatively short and reads as an announcement rather than a full report. It does not contain financial statements or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's capital market structure and listing plans.
2024-10-17 English
Telix Q3 2024 Revenue and Business Update 5 pages 275.1KB
Earnings Release Classification · 95% confidence The document is an ASX announcement titled 'Telix Q3 2024 Business Update Quarterly Revenue Exceeds AU$200M' dated 17 October 2024. It provides unaudited revenue figures for the quarter ended 30 September 2024 (Q3 2024), operational highlights, business unit updates, and reaffirmation of full year guidance. The document includes detailed business and financial performance commentary but does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report. It is a business update focusing on revenue and operational progress rather than a full quarterly report. The document also mentions capital raising and an acquisition but these are part of the broader business update rather than standalone capital/financing updates. Given the detailed quarterly revenue and operational update, this fits best as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is Earnings Release (ER) with high confidence.
2024-10-16 English
Andreas Kluge to Retire from Telix Board 2 pages 137.0KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 17 October 2024, announcing the retirement of a Non-Executive Director and Co-Founder, Andreas Kluge, from the Board. The content focuses on management changes and includes statements from the Chairman, CEO, and the retiring director. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a report but an announcement regarding a change in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length (7372 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2024-10-16 English
Appendix 3Z Final Director Notice (A Kluge) 2 pages 242.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, including shareholdings and related party contracts. The document is a formal notification of a director's personal share transactions and interests, which aligns with the definition of Director's Dealing filings. The document length is short (2597 characters) and contains no financial statements or report content, confirming it is a Director's Dealing notice rather than a financial report or announcement of a report.
2024-10-16 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.